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MicroRNAs (miRNAs) are small, noncoding 
RNAs. They function in various cellular pro-
cesses by targeting the 3 untranslated regions 
(UTRs) of target mRNAs (Bartel, 2004; He 
and  Hannon,  2004).  Differentially  expressed 
miRNAs in tumors inhibit or promote tumor 
development, progression, and metastasis by regu-
lating oncogenes or tumor suppressor genes 
(Calin and Croce, 2006).
The tumor suppressor p53 is a transcrip-
tion factor that induces or represses a large set 
of genes and miRNAs (Vogelstein et al., 2000; 
Hermeking, 2007; Chari et al., 2009). Previ-
ous studies have shown that deletions or mu-
tations of p53 are frequently found in cancers 
(Soussi,  2007;  Chari  et  al.,  2009),  and  that 
p53 is involved in tumor metastasis as well   
as  tumor  progression  (Lewis  et  al.,  2005; 
Ridgeway et al., 2006; Chen et al., 2007; Hansen   
et al., 2007).
Epithelial–mesenchymal  transition  (EMT) 
is necessary for many developmental processes, 
such as neural tube and mesoderm formation 
during  embryogenesis,  and  has  been  high-
lighted as a key process in tumor invasion, me-
tastasis and tumorigenicity (Yang and Weinberg, 
2008; Wellner et al., 2009). EMT, which repro-
grams transcription of tumor cells, is promoted 
by transforming growth factors (TGFs), such as 
TGFB1 (TGF1) and TGFB2 (TGF2; Thiery 
and  Sleeman,  2006).  Several  EMT-activating 
transcription factors: ZEB1 (dEF1, TCF8, and 
AREB6), ZEB2 (SIP1), SNAI1 (Snail), SNAI2 
(Slug), and TWIST involved in this process have 
been previously identified (Yang and Weinberg, 
2008).  Recently,  it  was  reported  that  the 
miR-200 family targets ZEB1 and ZEB2 and is 
significantly  down-regulated  in TGF-induced 
mesenchymal cells and cancer cells with mesen-
chymal characteristics (Gregory et al., 2008; Park 
et  al.,  2008).  Here,  we  have  expanded  the 
knowledge about EMT and p53. We show first 
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p53 suppresses tumor progression and metastasis. Epithelial–mesenchymal transition (EMT) 
is a key process in tumor progression and metastasis. The transcription factors ZEB1 and 
ZEB2 promote EMT. Here, we show that p53 suppresses EMT by repressing expression of 
ZEB1 and ZEB2. By profiling 92 primary hepatocellular carcinomas (HCCs) and 9 HCC cell 
lines, we found that p53 up-regulates microRNAs (miRNAs), including miR-200 and  
miR-192 family members. The miR-200 family members transactivated by p53 then repress 
ZEB1/2 expression. p53-regulated miR-192 family members also repress ZEB2 expression. 
Inhibition or overexpression of the miRNAs affects p53-regulated EMT by altering ZEB1 
and ZEB2 expression. Our findings indicate that p53 can regulate EMT, and that p53-
regulated miRNAs are critical mediators of p53-regulated EMT.
© 2011 Kim et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Vimentin (VIM) expression (Yang and Weinberg, 2008). EMT 
results in increased cell invasion and migration and is frequently 
accompanied by disseminated cell growth and changes in cellular 
morphology (i.e., cells become thin and elongated.). We found 
that p53 deletion causes significant changes in cell morphol-
ogy and dissemination corresponding to EMT characteristics   
(Fig. 1 A). In addition, p53 deletion or knock-down resulted in 
enhanced cell invasion (Fig. 1 B) and migration (Fig. 1, C and D).
that p53 prevents EMT by repressing ZEB1 and ZEB2 expres-
sion and, second, that p53-regulated miR-200 and miR-192 
family members are involved in p53-modulated EMT.
RESULTS AND DISCUSSION
p53 suppresses epithelial-mesenchymal transition
EMT-generated mesenchymal cells are characterized by down-
regulated CDH1 expression and up-regulated CDH2 and/or 
Figure 1.  p53 inhibition induces EMT resulting in increased cell invasion and migration. (A) Phase-contrast view of RKO (p53+/+ and p53/) 
cells. (B) C3A (stably expressing sh-control, sh-CTRL, or sh-p53) cells, RKO (p53+/+ and p53/) cells, and Hep3B (stably expressing empty vector, EV, or 
WT p53 expression vector [WTp53]) cells were subjected to in vitro invasion assay for 48 h. (C) RKO (p53+/+ and p53/) cells were subjected to in vitro 
migration assay for 24 h. (D) Wound-healing assay using RKO (p53+/+ and p53/) cells that were plated and disrupted with a 200-µl tip. 60 h after 
disruption, the cell layer was photographed. (E) Relative expression levels of CDH1 and VIM mRNA (left) and VIM protein (right) in RKO (p53+/+ and 
p53/) cells. (F) Relative expression of CDH1 and CDH2 mRNA (top) and protein (bottom) in C3A cells stably expressing sh-CTRL or sh-p53 and 
treated with DMSO or 10 µM nutlin-3 for 24 h. (top) Densitometry values of p53 protein levels were normalized with those of -actin protein levels. 
(A and D) A representative experiment out of three independent experiments. (B, C, E, and F) Data are mean ± SEM of three independent experiments 
and each measured in triplicate (**, P < 0.05; *, P ≤ 0.01). Bars, 50 µm.JEM VOL. 208, May 9, 2011  877
Brief Definitive Report
To verify that the changes in cell morphology and dis-
semination are caused by EMT, expression levels of epithelial 
and mesenchymal markers were compared with p53 expres-
sion level. The epithelial marker (CDH1) was consistently re-
pressed, whereas mesenchymal markers (CDH2 or  VIM) were 
induced by p53 inhibition (Fig. 1, E and F). In addition, p53 
activation using nutlin-3 (Vassilev et al., 2004) also induced 
CDH1, but reduced CDH2 expression levels (Fig. 1 F). These 
observations indicate that p53 inhibits EMT and causes de-
creased tumor invasion and migration.
p53 represses ZEB1 and ZEB2 expression through miRNAs
To identify EMT regulators that are involved in the p53- 
regulated EMT, we tested expression levels of the following 
known  EMT  activators:  SNAI1,  SNAI2, TGFB1, TGFB2, 
TWIST, ZEB1, and ZEB2. The expression levels of EMT ac-
tivators such as SNAI1, SNAI2, TGFB1, and TGFB2 were not 
induced by p53 inhibition (Fig. S1, A–D). TWIST was not de-
tected at either the mRNA or protein level (unpublished data). 
However, expression levels of ZEB1 and ZEB2 were signifi-
cantly repressed by p53 (Fig. 2, A and B and Fig. S2 A), suggesting 
a potent role of ZEB1 and ZEB2 in p53-regulated EMT.
First,  we  attempted  to  determine  whether  ZEB1  and 
ZEB2 are involved in p53-mediated EMT regulation. To as-
sess this hypothesis, ZEB1 and ZEB2 were knocked down in 
p53/ RKO cells by stable expression of short hairpin RNA 
(sh)-ZEB1 and sh-ZEB2. In p53/ RKO cells, the simulta-
neous repression of ZEB1 and ZEB2 significantly inhibited 
mesenchymal cell morphology and dissemination (Fig. 2 C). 
However, when ZEB1 or ZEB2 repression occurred sepa-
rately,  that  repression  did  not  inhibit  the  mesenchymal 
characteristics significantly (Fig. S2, B and C). Furthermore, 
simultaneous ZEB1 and ZEB2 repression decreased cell in-
vasive and migratory capacity, which was increased by p53 
knock-down or knock-out (Fig. 2, D and E). These results 
suggest that, together, ZEB1 and ZEB2 play a key role in 
p53-mediated EMT regulation.
Next, we examined the mechanism by which p53 represses 
ZEB1 and ZEB2 expression. ZEB1 protein levels were signifi-
cantly induced by p53 inhibition (Fig. 2, A and B). At the   
same time, ZEB1 mRNA levels were also significantly up-
regulated by p53 deletion or knock-down (Fig. S3 A). These 
findings suggest that ZEB1 is repressed by p53 at either the 
transcriptional or mRNA level. To examine whether ZEB1 is 
repressed by p53 at the transcriptional level, luciferase report-
ers containing the 5 promoter regions of ZEB1 were ex-
pressed  in  p53-expressing  C3A  cells  (C3A-sh-CTRL)  and 
p53 knocked-down C3A cells (C3A-sh-p53). Unexpectedly, 
we found that luciferase activities were higher in p53-expressing 
cells than in the p53 knocked-down cells (Fig. S3 B). This result 
indicates that p53 may activate rather than repress the transcrip-
tion of ZEB1 mRNA. However, p53 represses ZEB1 protein 
levels as we showed (Fig. 2, A and B). Thus, these results suggest 
that ZEB1 is repressed by p53 at the mRNA level.
ZEB2 mRNA levels were not significantly altered by p53 
(Fig. S3 A), although ZEB2 protein levels were dramatically 
Figure 2.  p53 inhibits EMT through ZEB1 and ZEB2 repression in 
a 3UTR-dependent manner. (A) Protein levels of ZEB1, ZEB2, and p53 
in RKO (p53+/+ and p53/) cells. (B) Protein levels of ZEB1, ZEB2, p53, 
and CDH1 in C3A-sh-CTRL and C3A-sh-p53 cells. (C) Phase contrast 
view of RKO (p53+/+ and p53/) cells stably expressing sh-CTRL or sh-
ZEB1/2. (D) In vitro invasion assay using C3A-sh-CTRL and C3A-sh-p53 
cells transfected with si-CTRL or si-ZEB1/2. (E) Wound-healing assay 
using RKO (p53+/+ and p53/) cells stably expressing sh-CTRL or sh-
ZEB1/2. A representative experiment out of three independent experi-
ments. (F) Luciferase assay of ZEB1 (RL-ZEB1) or ZEB2 (RL-ZEB2) 3UTR 
in C3A-sh-CTRL and C3A-sh-p53 cells. RL, Renilla luciferase; FL, Firefly 
luciferase. (A–C) A representative experiment out of two independent 
experiments. (D and F) Data are mean ± SEM of three independent ex-
periments and each is measured in triplicate (**, P < 0.05; *, P ≤ 0.01). 
Bars, 50 µm.878 p53-mediated EMT regulation through miRNAs | Kim et al.
He and Hannon, 2004). To investigate if ZEB1 and ZEB2 
mRNAs are repressed by p53-dependent miRNAs, luciferase 
reporters inserted with the 3 UTR of ZEB1 or ZEB2   
(Fig. S4 A) were expressed in cells stably expressing sh-CTRL   
or sh-p53. This resulted in decreased luciferase activities in 
p53-expressing cells (sh-CTRL) but not in p53 knocked-
down cells (sh-p53; Fig. 2 F), indicating that miRNAs may be 
involved in p53-repressed ZEB1 and ZEB2 expression.
miR-200 family members are regulated by p53
To  identify  miRNAs  that  are  regulated  by  p53,  we  used 
miRNA microarray analysis (Liu et al., 2004). We analyzed 92 
primary hepatocellular carcinomas (HCCs) and 9 HCC cell 
lines that were classified by p53 status (Materials and meth-
ods). The microarray data from the primary HCC samples 
(Table S1) were compared with the data from the HCC cell 
repressed by p53. These findings suggest that ZEB2 is re-
pressed by p53 at the posttranscriptional level such as the 
translational or protein (posttranslational) level. To examine 
whether p53 regulates ZEB2 expression at the protein level, 
ZEB2 expression vectors lacking the 3 UTR were intro-
duced into p53/ cells with either the empty or p53 expres-
sion vectors. However, p53 did not reduce exogenous ZEB2 
protein levels (Fig. S3 C). These results indicate that the ZEB2 
expression is regulated by p53 at the translational level and 
that the 3 UTR of ZEB2 mRNA may be implicated in the 
mechanism of p53-repressed ZEB2 expression.
All of these findings indicate that the expression of ZEB1 
and ZEB2 is regulated at the mRNA or translational level.   
In addition, the findings are consistent with the knowledge 
that  miRNAs  target  mRNAs,  resulting  in  degradation   
or translational inhibition of the mRNAs (Bartel, 2004;   
Figure 3.  miR-200 and miR-192 family members are regulated by p53. (A) Expression levels of miR-141, miR-200c, and miR-34a in nine HCC cell 
lines harboring WT p53, p53 deletion (Null), or mutant p53 (Mutant). (B) Relative expression of miR-200 family members, miR-34a (positive control), and 
miR-146b (negative control) in C3A-sh-CTRL and C3A-sh-p53 cells. (C) Relative expression levels of miR-200 family members, miR-192, miR-34a (positive 
control), and miR-146b (negative control) in Hep3B cells stably expressing WT p53, mutant (MUT) p53, or empty vectors. (D) Expression levels of miR-141, 
miR-200c, miR-192, and miR-215 in RKO (p53/ and p53+/+) cells. (E) Expression levels of miR-200 family members in MEF (p53/ and p53+/+) cells 
with (right) or without (left) doxorubicin (200 ng/ml) treatment for 24 h. (A–E) Data are mean ± SEM of three independent experiments and each is mea-
sured in triplicate (**, P < 0.05; *, P ≤ 0.01).JEM VOL. 208, May 9, 2011  879
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miR-200c, we found that the miRNAs are highly expressed 
in HCC cell lines harboring WT p53 (Fig. 3 A). In addition, 
miR-200 and miR-192 family members were repressed by 
p53 inhibition and/or induced by p53 activation in various 
cell types (Fig. 3, B-E; and Fig. S5 A).
To determine whether p53 regulates miR-200 family mem-
bers at the transcriptional level, various regions of miR-200 
family members were amplified by semiquantitative RT-PCR 
(sqRT-PCR). These include portions of the primary miRNAs 
(primary transcripts) that are not located in the section contain-
ing precursor miRNAs (Fig. 4 A). Expression levels of these   
lines (Table S2). From these comparisons, we identified nine 
miRNAs (miR-141, miR-192, miR-193b, miR-194, miR-
200b, miR-200c, miR-215, miR-224, and miR-34a) as p53 
up-regulated miRNAs.
Although  previously  published  data  have  shown  that 
miR-34a and miR-192 family members (miR-192 and miR-
215) can be regulated by p53 (Chang et al., 2007; He et al., 
2007; Raver-Shapira et al., 2007; Braun et al., 2008; Georges 
et al., 2008; Pichiorri et al., 2010), the regulation of miR-200 
family by p53 in tumor samples has never been investigated 
before. By examining the expression levels of miR-141 and 
Figure 4.  miR-200 family members are directly regulated by p53 at the transcriptional level. (A) sqRT-PCR of miR-200 family clusters. The re-
gions (A–F) amplified by sqRT-PCR are indicated with blue-colored bars in a schematic (top). (B) Schematic view of miRNA-200 family clusters and chro-
mosomal locations of TSS and putative p53BS (blue ovals: 200c1, 200c2, and 200b). Gray and white fragments represent 500 bp in length. Small gray 
arrows indicate primers (F, forward; R, reverse) used for the constructs of luciferase assay (D). Large black arrows indicate locations of precursor miRNAs. 
(C) ChIP analysis using C3A cells. 200c1 and 200c2 designate p53BSs of miR-200c–141 cluster and 200b designates p53BS of miR-200b–429 cluster. 
200c AR designates a region adjacent (200 bp from 200c2) to p53BS of miR-200c–141 cluster. 200c AR and GAPDH are used as negative controls. Input 
represents 1% of the total chromatin used in this analysis. (D) Luciferase assay of 5 promoters of miR-200 family clusters in C3A-sh-CTRL and C3A- 
sh-p53 cells. The regions inserted into luciferase reporters are depicted in B. RL, Renilla luciferase; FL, Firefly luciferase. (E, top) Luciferase assay of 5 pro-
moter with WT or mutant (MUT) p53BSs of miR-200 family clusters in C3A-sh-CTRL and C3A-sh-p53 cells. (bottom) Sequence information on p53BSs 
mutations. (A and C) A representative experiment out of two independent experiments. (D and E) Data are mean ± SEM of three independent experiments 
and each is measured in triplicate (**, P < 0.05; *, P ≤ 0.01).880 p53-mediated EMT regulation through miRNAs | Kim et al.
Next, we examined the function of endogenous miR-200 
and miR-192 family members using luciferase reporters.   
Inhibition of miR-141 or miR-200c induced luciferase ac-
tivities of ZEB1 and ZEB2 3 UTRs (Fig. 5 C). Inhibition of 
miR-192 or miR-215 induced luciferase activity of ZEB2   
3 UTR (Fig. 5 D) and miR-192 inhibition induced ZEB2 
protein levels (Fig. S5 D, right). To further test the function of 
the miR-200 family in p53-repressed ZEB1 and ZEB2 ex-
pression, C3A-sh-CTRL and C3A-sh-p53 cells were transfected 
with luciferase reporters containing the ZEB1 or ZEB2 3 UTR 
with mutations in miR-200 family binding sites (Fig. S4 B). The 
mutations in the miR-200 family binding sites resulted in 
more significant induction of luciferase activities in p53- 
expressing cells than in p53 knocked-down cells (Fig. 5 E). 
These results indicate that miR-200 and miR-192 family 
members have a substantial function in p53-mediated ZEB1/2 
repression. In addition, miR-141 and miR-200c expression 
levels correlated to the CDH1 expression level in primary 
HCC samples, supporting the role of endogenous miR-200 
family in EMT (Fig. S5 E). Collectively, our results demon-
strate that the miR-200 and miR-192 family members regu-
lated by p53 play a critical role in p53-repressed EMT.
In summary, we show that p53-regulated miRNAs pre-
vent EMT by repressing ZEB1 and ZEB2 expression. Our re-
sults complement a recent study that shows p53-regulated EMT 
through miR-200c-ZEB1 (Chang et al., 2011). By sequencing 
and profiling 92 HCC samples, we further revealed that miR-
200 and miR-192 family members are p53-regulated miRNAs 
and regulate ZEB1 and ZEB2 protein expression at the 
posttranscriptional level. In addition, our results indicate that 
both ZEB1 and ZEB2, which are targeted by a cohort of 
p53-regulated miRNAs, are involved in p53-modulated EMT. 
Many studies have shown that both p53 and EMT have a 
critical role in tumor invasion, metastasis, and tumorigenicity 
(Lewis et al., 2005; Ridgeway et al., 2006; Chen et al., 2007; 
Hansen et al., 2007; Yang and Weinberg, 2008; Wellner et al., 
2009). Thus, our observations may provide new insights into 
the role of p53 and miRNAs in tumor invasion, metastasis, 
and tumorigenicity.
MATERIALS AND METHODS
Patients and primary HCC samples. This study was approved by an In-
stitutional Human Research Review Board (RBM 2005–019). We followed 
established protocols regarding informed consent and anonymity. Our re-
search team collected and analyzed tissue from 92 HCC patients. Tissue 
specimens were obtained retrospectively under strict anonymity from histor-
ical collections established in surgery or pathology units of hospitals. All   
samples were fresh-frozen in liquid nitrogen after surgery and kept at   
80°C.  Frozen  tissue  samples  were  homogenized  using  the Tissue  Ruptor   
(QIAGEN) before RNA extraction. Total RNA was extracted using Tri- 
Reagent (MRC) in accordance with the manufacturer’s instructions. To deter-
mine TP53 (p53) status of the primary HCC samples, PCR products of TP53 
exons 4–11 from genomic DNA were directly sequenced because >95% of 
TP53 mutations in HCC occur in these exons. Of 92 samples, 62 harbored WT 
TP53. However, TP53 was mutated or deleted in 30 of the samples.
Migration and invasion assays. Cell migration and invasion assays were 
performed with Cell Migration Assay kit (Millipore) and Cell Invasion Assay 
primary miRNA regions in miR-200c–141 (Fig. 4 A, A and B) 
and miR-200b–429 (Fig. 4 A, C–F) clusters were significantly 
reduced by p53 inhibition, suggesting that p53 regulates miR-
200 family members at the transcriptional level.
It has been reported that the clusters of miR-200c–141 
and miR-200b–429 are encoded by single polycistronic tran-
scripts, and putative transcriptional start sites (TSSs) of the 
transcripts have also been identified (Bracken et al., 2008; 
Burk et al., 2008). Here, we used MatInspector to analyze 
putative p53 binding sites (p53BSs) in 5 promoter regions of 
the transcripts (Cartharius et al., 2005). Using the prediction 
tool, we found two putative p53BSs (200c1 and 200c2) and 
one putative p53BS (200b) in the 5 promoter regions of the 
miR-200c–141 and miR-200b–429 clusters (Fig. 4 B).
To verify the prediction for the p53BSs, we performed 
chromatin immunoprecipitation (ChIP) assay in C3A cells 
using p53-specific antibody. The result of ChIP assay shows 
the direct binding of p53 on the p53BSs (Fig. 4 C). Luciferase 
activities driven by the 5 promoter regions (Fig. 4 B) of miR-
200c–141 and miR-200b–429 clusters were induced in p53-
expressing (C3A-sh-CTRL) cells, but not in p53-knock-down 
(C3A-sh-p53) cells (Fig. 4 D, lane 2 and 6). In addition, lucif-
erase reporters including each p53BS (Fig. 4 B) of miR-200c–
141 cluster also showed higher activities in C3A-sh-CTRL 
than C3A-sh-p53 cells (Fig. 4 D, lane 3 and 4). To further 
confirm the function of the p53BSs, they were mutated as in-
dicated (Fig. 4 E, bottom) and luciferase reporters containing 
the 5 promoter region mutations were expressed in C3A- 
sh-CTRL and C3A-sh-p53 cells. To compare the relative re-
duction of luciferase activity in the cells, luciferase activities of 
the mutated luciferase reporters were normalized with those 
of WT luciferase reporters. As a result, the mutations in the 
p53BSs resulted in more significantly reduced luciferase activi-
ties in C3A-sh-CTRL cells than in C3A-sh-p53 cells (Fig. 4 E, 
top). Collectively, these results indicate that p53 directly acti-
vates transcription of miR-200 family members.
p53-regulated miR-200–192 family is involved  
in p53-mediated EMT
It has been reported that miR-200 family members target 
ZEB1 and ZEB2 mRNAs (Burk et al., 2008; Gregory et al., 
2008;  Park  et  al.,  2008),  and  that  miR-192  targets  ZEB2 
mRNA (Kato et al., 2007). We also observed that miR-200 
family members repress ZEB1 and ZEB2 expression. This   
resulted in increased CDH1 and decreased VIM expression   
(Fig. S5, B and C). In addition, we observed that miR-192 re-
presses ZEB2, but not ZEB1, expression (Fig. S5 D, left). We next 
examined the role of miR-200 and miR-192 family members 
in p53-mediated EMT regulation. By overexpressing miR-141, 
miR-200c, and/or miR-192, mesenchymal characteristics 
(e.g., changes to cell morphology and enhanced dissemination, 
invasion, and migration) caused by p53 deletion were signifi-
cantly inhibited (Fig. 5, A and B). These results suggest that the 
miR-200 family members and miR-192 are involved in p53-
mediated EMT regulation and that miR-192 targeting ZEB2 
but not ZEB1 also has a role in p53-regulated EMT.JEM VOL. 208, May 9, 2011  881
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OH). The cells were cultured in DME with 10% FBS. RKO cells stably 
transfected with sh-ZEB1 and sh-ZEB2 were generated by lentiviral sh-ZEB1 
transfection and puromycin selection, followed by ZEB2 sh-RNA constructs 
transfection and hygromycin b selection. Control RKO (p53/ sh-CTRL 
and p53+/+ sh-CTRL) cells were also generated by the same procedures using 
lentiviral sh-CTRL and control sh-RNA constructs. 5-fluorouracil (5-FU) 
and Doxorubicin were purchased from Sigma-Aldrich. Nutlin-3a was ob-
tained from Cayman Chemical Company. G418 was from purchased from 
Roche, and puromycin was purchased from Santa Cruz Biotechnology, Inc. 
Hygromycin b was obtained from Sigma-Aldrich.
Plasmids, oligonucleotides, and transfections. The p53 sh-RNA plas-
mid and lentiviral particles of sh-ZEB1, sh-ZEB2, and sh-CTRL were pur-
chased from Santa Cruz Biotechnology, Inc. ZEB2 and control sh-RNA 
constructs were purchased from SA Biosciences. The Zeb2-HA expression 
plasmid was a gift from A.H. Lund (University of Copenhagen, Copenhagen, 
Denmark). Precursor miRNAs (Pre-miR) were obtained from Ambion, and 
LNA-miRNA inhibitors (LNA-miR) were obtained from Exiqon. p53 ex-
pression plasmids (WT or mutant) were cloned from the cDNA of HepG2 
(WT), Huh7 (Y220C), or SNU-449 (A161T) into pcDNA3.1 (Invitrogen) 
using BamH1 and EcoRI. For promoter assays, the 5 promoter regions indi-
cated in the figures were amplified by PCR. The PCR products amplified 
kit (Millipore). Both procedures were carried out in accordance with the 
manufacturer’s instructions. In brief, cells were starved in serum-free medium 
for 24 h, and then plated in the chamber (8 µm pole size) containing un-
coated polycarbonate membrane (migration assay) or coated with a thin layer 
of polymerized collagen (invasion assay). The chamber was incubated in a 
well containing 10% serum-containing medium for 24 h (migration assay) or 
48 h (invasion assay). The cells on the bottom of the chamber were stained 
and dislodged. We then measured those cells in accordance with the manu-
facturer’s instructions.
Wound-healing assay. When cultured cells reached 90% confluence, they 
were starved for 24 h by incubation in serum-free medium. After the 24 h 
starvation, cells were scratched with a pipette tip and cultured in medium 
containing 10% FBS. Recovery of the disruption was observed for up to 60 h.
Cells, reagents, and antibiotics. HCC cell lines (HepG2, C3A, Hep3B, 
Huh7, PLC/PRF/5, SNU-387, SNU-423, SNU-449, and SNU-475) were 
cultured as recommended by the American Type Culture Collection. RKO 
(p53/ and p53+/+) cells were gifts from B. Vogelstein (Johns Hopkins 
University, Baltimore, MD). The cells were maintained in Eagle’s Minimum 
Essential Medium with 10% FBS (Sigma-Aldrich). Mouse embryonic fibroblasts 
(MEFs) were gifts from G. Leone (The Ohio State University, Columbus, 
Figure 5.  miR-200 and miR-192 family members regulate p53-mediated EMT by targeting ZEB1 and ZEB2. (A) p53+/+ and p53/ RKO cells 
were transfected twice a week for 2 wk with indicated premiRs (50 nM). Cells were then photographed. A representative experiment out of three indepen-
dent experiments is shown. (B) RKO (p53+/+ and p53/) cells transfected with indicated premiRs were subjected to in vitro invasion (top) and migration 
(bottom) assays. (C) C3A cells were transfected with luciferase constructs driven by 3UTRs of ZEB1 or ZEB2 (RL-ZEB1, RL-ZEB2), together with scrambled 
miRNA inhibitor (Scr) or inhibitors of miR-141 (-141) or miR-200c (-200c). RL, Renilla luciferase; FL, Firefly luciferase. (D) RKO (p53+/+) cells were trans-
fected with luciferase constructs driven by 3UTRs of ZEB1 or ZEB2 (RL-ZEB1, RL-ZEB2), together with scrambled miRNA inhibitor (Scr) or inhibitors of 
miR-192 (-192) or miR-215 (-215). (E) Luciferase assay using C3A-sh-CTRL and C3A-sh-p53 cells transfected with pCIneo-hRL constructs containing 
ZEB1 or ZEB2 3UTR with (200MUT) or without (WT) mutations in miR-200 family binding sites. (B-E) Data are mean ± SEM of three independent experi-
ments and each is measured in triplicate (**, P < 0.05; *, P ≤ 0.01). Bars, 50 µm.882 p53-mediated EMT regulation through miRNAs | Kim et al.
was prepared and digested with EZ-Zyme Chromatin Prep kit (Millipore). 
The digested sample was subjected to ChIP assay using EZ-Magna ChIP kit 
(Millipore). All procedures were done as per the manufacturer’s instructions. 
Anti-p53 (DO-1; Santa Cruz Biotechnology, Inc.) was used for the assay.   
After ChIP assay was performed, the DNA sample was amplified by PCR 
using the primers listed in Table S3.
Luciferase assay. Cells were plated in 24- or 48-well plates 24 h before trans-
fection. All plasmids constructed with pGL4-luc2 vectors were cotransfected 
with control Renilla luciferase plasmid (pGL4-hRluc/TK). pCIneo-hRL-ZEB 
constructs were cotransfected with control pGL3 vectors (firefly luciferase vec-
tor).  The ratio of experimental plasmid to control plasmid was 10:1. psiCHECK2 
vectors with 3 UTR of ZEB1 or ZEB2 were transfected in a similar manner. 
Luciferase assays were performed using the Dual-Luciferase Reporter Assay 
System (Promega). In brief, 24–48 h after transfection, cell lysates were prepared 
by incubating with 1× passive lysis buffer for 15 min at room temperature. Cell 
lysates were transferred in triplicate to 96-well plates and analyzed using Glo-
Max Luminometer (Promega) according to the manufacturer’s instructions.
Immunocytochemistry. Cells grown in chamber slides (Laboratory-Tek) 
were washed three times with PBS and fixed with 4% formaldehyde for 15 min 
at room temperature. After three PBS washes, cells were permeabilized with 
0.25% Triton X-100 in PBS. Cells were incubated in PBS containing 2% 
BSA, followed by overnight incubation at 4°C with VIM antibody. The sec-
ondary antibody was incubated for 1 h at room temperature.
Statistics. All graph values represent means ± SEM from three independent 
experiments with each measured in triplicate. The differences between two 
groups were analyzed with unpaired two-tailed Student’s t test. P < 0.05 was 
considered statistically significant and indicated with asterisks as described in 
figure legends.
Online supplemental material. Fig. S1 shows that known EMT-activators 
other than ZEB1 and ZEB2 are not involved in p53-suppressed EMT. Fig. S2 
shows p53-repressed ZEB1/2 expression in p53-null Hep3B cells and the 
effect of either ZEB1 or ZEB2 knock-down in p53-suppressed EMT. Fig. S3 
shows that p53-repressed ZEB1 and ZEB2 expression occurs in the mRNA 
or translational level, but not in the transcriptional or posttranslational level. 
Fig. S4 shows the schematics of luciferase constructs used for luciferase ac-
tivities of ZEB1 or ZEB2 3 UTR. Fig. S5 shows p53-mediated regulation 
of miR-200 and miR-192 family members and the regulation of ZEB1/2 
and EMT markers (CDH1/VIM) through the miRNAs. Table S1 shows the 
list of p53-regulated miRNAs identified in primary HCC samples. Table 
S2 shows the list of p53-regulated miRNAs identified in nine HCC cell 
lines. Table S3 shows information of primers. Table S4 shows information 
of probes used for qRT-PCR. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20110235/DC1.
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